Volume 3.41 | Oct 20

Mammary Cell News 3.41, October 20, 2011
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Protein That Fuels Lethal Breast Cancer Growth Emerges as Potential New Drug Target
A protein in the nucleus of breast cancer cells that plays a role in fueling the growth of aggressive tumors may be a good target for new drugs, reports a research team. [Press release from Duke Medicine discussing online prepublication Cancer Cell] Press Release | Abstract


ON83_EpiCultVideo_645x110.jpg
PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH

SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity
To investigate the physiological functions of SIRT2 in development and tumorigenesis, scientists disrupted Sirt2 in mice. [Cancer Cell] Abstract | Press Release

Estrogen Receptor–Co-Factor–Chromatin Specificity in the Transcriptional Regulation of Breast Cancer
Here, researchers present the most comprehensive chromatin-binding landscape of estrogen receptor α co-regulatory proteins to date. [EMBO J] Abstract


Subtype and Pathway Specific Responses to Anticancer Compounds in Breast Cancer
In a test of 77 therapeutic compounds, nearly all drugs showed differential responses across different breast cancer cell lines, and approximately one third showed subtype-, pathway-, and/or genomic aberration-specific responses. [Proc Natl Acad Sci USA] Abstract


Estrogen Induces Apoptosis in Estrogen Deprivation-Resistant Breast Cancer through Stress Responses as Identified by Global Gene Expression Across Time
Data indicates that 17β-estradiol induced apoptosis through endoplasmic reticulum stress and inflammatory responses in advanced antihormone-resistant breast cancer. [Proc Natl Acad Sci USA] Abstract


Lactoferrin-Endothelin-1 Axis Contributes to the Development and Invasiveness of Triple Negative Breast Cancer Phenotypes
Here investigators discovered that lactoferrin efficiently downregulates the levels of ERα, PR and HER-2 receptors in a proteasome-dependent manner in breast cancer cells, and accounts for the loss of responsiveness to ER- or HER-2- targeted therapies. [Cancer Res] Abstract


Overexpressed hPTTG1 Promotes Breast Cancer Cell Invasion and Metastasis by Regulating GEF-H1/RhoA Signaling
Here, scientists showed that Rho guanine nucleotide exchange factor-H1 (GEF-H1) was transcriptionally activated by human pituitary tumor-transforming gene 1 (hPTTG1), thereby promoting breast cancer metastasis. [Oncogene] Abstract


CERT Depletion Predicts Chemotherapy Benefit and Mediates Cytotoxic and Polyploid-Specific Cancer Cell Death through Autophagy Induction
Using an integrative functional genomics approach, researchers find that CERT-specific multidrug sensitization is associated with enhanced autophagosome–lysosome flux, resulting from the expression of LAMP2 following CERT silencing in colorectal and HER2+ breast cancer cell lines. [J Pathol] Abstract | Press Release

Functional Implications of Structural Predictions for Alternative Splice Proteins Expressed in Her2/Neu–Induced Breast Cancers
Here investigators exploit the state-of-the-art structure prediction method I-TASSER to analyze the structural and functional consequences of alternative splicing of proteins differentially expressed in a breast cancer model. [J Proteome Res] Abstract


CLINICAL RESEARCH

Risk of Recurrence and Chemotherapy Benefit for Patients with Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated with Pathologic and Clinical Factors
Adding clinicopathologic measures did not seem to enhance the value of recurrence score (RS) alone nor the individual biology RS identified in predicting chemotherapy benefit. [J Clin Oncol] Abstract | Press Release

Characteristics of Triple-Negative Breast Cancer in Patients with a BRCA1 Mutation: Results from a Population-Based Study of Young Women
Scientists tested whether there are distinguishing features of triple-negative breast cancer after BRCA1 mutation status has been taken into account. [J Clin Oncol] Abstract


Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
The purpose of this study is to assess the predictive value of Ki67 expression in postmenopausal hormone receptor-positive early breast cancer patients who were either treated with adjuvant tamoxifen (TAM) alone or with TAM followed by anastrozole. [Clin Cancer Res] Abstract


ALDEFLUORBreastCSC_645x110.jpg
SCIENCE NEWS
Halozyme Announces Positive Results from Roche’s Subcutaneous Herceptin Phase III Trial
Halozyme Therapeutics, Inc. announced that the Phase III HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion. [Halozyme Therapeutics Inc.] Press Release
INDUSTRY NEWS
Breast Centers at New York-Presbyterian/Columbia and New York-Presbyterian/Weill Cornell Are Manhattan’s First to be Accredited by the National Accreditation Program for Breast Centers
New York-Presbyterian Hospital and its two affiliated medical colleges have the only two breast centers in Manhattan that are fully accredited by the National Accreditation Program for Breast Centers. [New York-Presbyterian Hospital] Press Release


Susan G. Komen for the Cure® Announces $250,000 Investment to Improve Breast Health Care in Brazil
Susan G. Komen for the Cure® announced $250,000 in grants over the next year to Brazil breast cancer organizations. [Susan G. Komen for the Cure®] Press Release


Maryland Stem Cell Research Commission Issues Requests for Applications
Per the Maryland Stem Cell Commission (Commission) meeting on Sept.15, 2010, the Commission has issued three official Requests for Applications for funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act. [Maryland Stem Cell Research Fund] Press Release


Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
Genesis Biopharma, Inc. announced it has entered into a Patent License Agreement with the National Institutes of Health (NIH). [Genesis Biopharma, Inc.] Press Release
POLICY NEWS
Administrative Supplements to NCI-funded Research Projects: Funding to Advance Research on Cancers in Women (OT-CA-12-001) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW National Conference on Biopharmaceuticals & Healthcare
November 4-5, 2011
Bangalore, India

NEW Days of Molecular Medicine 2011 – Re-Engineering Regenerative Medicine
November 10-12, 2011
Hong Kong

NEW 21st Asia Pacific Cancer Conference 2011
November 10-12, 2011
Kuala Lumpur, Malaysia

NEW AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
November 12-16, 2011
San Francisco, United States

Visit
our events page to see a complete list of events in the mammary cell community.
JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Research Fellow in Breast Cancer Research (Monash University)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us